Prostate Cancer

Conference Coverage

Real-World Utilization of Advanced Therapies for Metastatic Castration-Sensitive Prostate Cancer

06/14/2021

In a large representative sample of US patients with metastatic castration-sensitive prostate cancer, less than one-third of patients received advanced therapies by 2018, and this was especially less frequent in Black patients.

In a large representative sample...

06/14/2021

Journal of Clinical Pathways

Videos

Dr Tagawa Talks Final Analysis Results of the TITAN Study

06/08/2021

Scott Tagawa, MD, MS, FACP, provides commentary on the results of TITAN, a phase III study of apalutamide in patients with mCSPC receiving androgen deprivation therapy.

Scott Tagawa, MD, MS, FACP,...

06/08/2021

Oncology

Interview

Dr Labanca Talks Use of Non-Canonical AR Signaling, Ketone Body Fuel in CRPC

05/03/2021

Estefania Labanca, PhD, discusses data on CRPC progression and the use of non-canonical AR signaling and ketone body fuel which were presented at the AACR Annual Meeting.

Estefania Labanca, PhD,...

05/03/2021

Oncology

Conference Insider

Managing Testosterone Levels When Dosing is Delayed for Prostate Cancer

03/19/2021

In a study presented at the NCCN annual congress, Gel-LA was more likely to suppress testosterone rates over an extended period of time than Msphere-LA.

In a study presented at the NCCN...

03/19/2021

Oncology

Videos

Dr Tagawa Reviews the Role of ADT in COVID-19 in Prostate Cancer

03/09/2021

Scott Tagawa, MD, MS FACP, discusses the impact of ADT on the clinical course of COVID-19 in patients with prostate cancer.

Scott Tagawa, MD, MS FACP,...

03/09/2021

Oncology

Podcasts

Dr Saad Highlights Results Following the ACIS Study

02/20/2021

Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.

Fred Saad, MD, discusses the...

02/20/2021

Oncology

Videos

Dr Feng Discusses Molecular Determinants of Response to APA in nmCRPC

02/20/2021

Felix Feng, MD, talks about identifying molecular determinants of response to apalutamide in nonmetastatic CRPC in the SPARTAN trial.

Felix Feng, MD, talks about...

02/20/2021

Oncology

Interview

Dr Cohen Reveals CCR Score May Offer ADT-Free Therapy in Higher-Risk Prostate Cancer

02/16/2021

Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.

Todd Cohen, MD, highlights how...

02/16/2021

Oncology

Videos

Dr Tward Discusses CCR Scores Accurately Guiding Treatment for Prostate Cancer

02/16/2021

Jonathan Tward, MD, discusses how the link between clinical cell-cycle risk score and post-RT metastasis can identify patients eligible to forgo combined ADT.

Jonathan Tward, MD, discusses...

02/16/2021

Oncology